Background: Breast cancer is a major health issue for women in Africa. This study aims to assess the burden of the disease using the latest estimates from Global Cancer Observatory 2022.
Methods: Data were sourced from the Global Cancer Observatory 2022. Age-standardized incidence rates (ASIR) and mortality rates (ASMR) per 100,000 person-years were calculated using direct age standardization based on the Segi-Doll World standard population. Pearson's correlation coefficient was employed to assess the relationship between the Human Development Index (HDI) and both incidence and mortality rates. Projections for breast cancer cases and deaths by 2050 were estimated based on global demographic forecasts.
Results: In 2022, Africa reported an estimated 198.3 thousand new breast cancer cases and 91.3 thousand deaths. Nigeria reported the highest incidence (32,278) and deaths (16,332). Algeria had the highest ASIR (61.9/100,000) while Cameroon had the highest ASMR (27.4/100,000). ASMR increased with age, surged in individuals over 70 in Africa. Chad had the earliest ASIR peak age at 40-49 years (40.3/100,000) and earliest ASMR peak age at 50-59 years (24.1/100,000). A positive correlation was observed between HDI and incidence rates. Projections suggest that by 2050, Nigeria and Egypt will bear the highest disease burden, with Tanzania and Zambia experiencing nearly 200 % rise in incidence, while Guinea and Niger will see mortality rates surge by over 200 %.
Conclusions: Breast cancer mortality is higher in low socio-economic countries. Efforts should focus on low socio-economic countries, implementing rapid intervention measures to mitigate the growing cancer crisis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ejso.2025.109627 | DOI Listing |
BMC Cancer
January 2025
Young Academy of Gynecologic Oncology (JAGO), Nord-Ostdeutsche Gesellschaft für Gynäkologische Onkologie (NOGGO), Berlin, Germany.
Background: The integration of immune checkpoint inhibitors (ICIs) into routine gynecologic cancer treatment requires a thorough understanding of how to manage immune-related adverse events (irAEs) to ensure patient safety. However, reports on real-world clinical experience in the management of ICIs in gynecologic oncology are very limited. The aim of this survey was to provide a real-world overview of the experiences and the current state of irAE management of ICIs in Germany, Switzerland, and Austria.
View Article and Find Full Text PDFBMC Cancer
January 2025
Division de la Recherche Clinique, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand, 63011, France.
Background: Over the past twenty years, the post-cancer rehabilitation has been developed, usually in a hospital setting. Although this allows better care organization and improved security, it is perceived as stressful and restrictive by the "cancer survivor". Therefore, the transfer of benefits to everyday life is more difficult, or even uncertain.
View Article and Find Full Text PDFBreast Cancer
January 2025
Tepe Prime, MKA Breast Cancer Clinic, 06800, Ankara, Turkey.
Breast Cancer Res Treat
January 2025
Google Health, 1600 Amphitheatre Pkwy, Mountain View, CA, 94043, USA.
Purpose: Many breast centers are unable to provide immediate results at the time of screening mammography which results in delayed patient care. Implementing artificial intelligence (AI) could identify patients who may have breast cancer and accelerate the time to diagnostic imaging and biopsy diagnosis.
Methods: In this prospective randomized, unblinded, controlled implementation study we enrolled 1000 screening participants between March 2021 and May 2022.
Mol Biol Rep
January 2025
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Background: The identification of circulating potential biomarkers may help earlier diagnosis of breast cancer, which is critical for effective treatment and better disease outcomes. We aimed to study the role of circ-FAF1 as a diagnostic biomarker in female breast cancer using peripheral blood samples of these patients, and to investigate the relation between circ-FAF1 and different clinicopathological features of the included patients.
Methods And Results: This case-control study enrolled 60 female breast cancer patients and 60 age-matched healthy control subjects.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!